WeVote
Log In

Bill

Bill

A 3852

Relates to the tax exemption of capital improvements to residential buildings

2025 Regular Session Introduced by Lester Chang and 4 co-sponsors

Establish a hospital-based psilocybin therapy pilot program under Dept. of Health with an 11-member advisory board; $6 million funding to study statewide delivery and research.

REFERRED TO REAL PROPERTY TAXATION
0
WeVote Research Nonpartisan
Bill Summary · A 3852

Summary — A3852: “Psilocybin Behavioral Health Access and Services Act” (and subsequent committee substitutes)

Status: Introduced Feb. 22, 2024; multiple Assembly committee substitutes (June 17, 2024; Nov. 24, 2025). Reported out of Senate committee with amendments 11/24/2025; referred to Assembly Appropriations. Companion: S2283.

Purpose / Intent

The bill seeks to authorize and regulate the production and therapeutic use of psilocybin (psilocybin/psilocin) to expand behavioral health care options for adults. The legislative intent includes creating safe, supervised settings for psilocybin-assisted experiences, improving behavioral health outcomes, and developing a statewide approach to access, oversight, and research.

Key provisions (evolving across versions)

  • Introduced version (Feb 2024)

    • Broad “Psilocybin Behavioral Health Access and Services Act” establishing a comprehensive regulatory scheme: licensure of psilocybin product manufacturers, service centers, testing labs, and service facilitators; defined required sessions (preparation, administration, integration); restricted access to adults 21+.
    • Created a Psilocybin Advisory Board in the Department of Health to advise on rules and licensing.
    • Included decriminalization and expungement of certain past psilocybin offenses (production, possession, use, distribution).

  • Assembly Committee Substitute (June 17, 2024)

    • Refined definitions (patient vs. client), clarified roles for behavioral health care providers, and expanded licensing/regulatory detail. (Did not reflect decriminalization language in the truncated substitute text.)

  • Assembly Committee Substitute (Nov 24, 2025)

    • Recast as a Psilocybin Behavioral Health Access and Therapy Pilot Program.
    • Establishes a Psychedelic Therapy and Research Advisory Board (11 members) to oversee the pilot.
    • Pilot administered by the Department of Health; targets participation by selected hospitals (defined regional structure: Northern, Central, Southern).
    • Appropriates $6 million to fund the pilot and research that complies with FDA/DEA requirements.
    • Pilot aims to support hospital-based psilocybin research and to evaluate a potential statewide delivery model.

Who would be affected

  • Adults 21+ who may be referred for psilocybin services (or patients in pilot hospitals).
  • Health care practitioners, behavioral health providers, hospitals, community organizations participating in pilot research.
  • Prospective psilocybin manufacturers, service center operators, facilitators, and testing laboratories (in versions that authorize licensing).
  • State Department of Health (program oversight) and advisory boards.
  • Criminal justice subjects potentially affected by decriminalization/expungement in the original introduced text (note: later substitutes pivot to regulated/licensed or pilot research approaches).

Procedural / timeline aspects

  • Introduced 2/22/2024; committee substitutes adopted by Assembly Health Committee (6/17/24 and 11/24/25).
  • Nov. 24, 2025 substitute reported out of Senate committee with amendments and referred to Assembly Appropriations Committee.
  • The Nov. 2025 substitute requires board appointments within 60 days of enactment; pilot commences upon hospital selection; $6M appropriation included.

Notes / caveats

  • The bill’s scope shifted across substitutes from a full regulatory framework (including decriminalization/expungement) toward a state-funded hospital research pilot program. Readers should consult the latest committee substitute text and amendment history to determine which provisions remain under active consideration.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.